Skip to content
Collegium Pharmaceutical
Medical Affairs
Mobile Menu Toggle navigation
Collegium Pharmaceutical
Medical Affairs
  • Resources
    • Resources
    • Upcoming Meetings
  • Medical Information
  • Education
  • Request a Follow-Up
  • Keep Me Updated
  • Resources
    • Resources
    • Upcoming Meetings
  • Medical Information
  • Education
  • Request a Follow-Up
  • Keep Me Updated
Collegium Pharmaceutical
  • Resources
    • Resources
    • Upcoming Meetings
  • Medical Information
  • Education
  • Request a Follow-Up
  • Keep Me Updated

A new abuse-deterrent opioid–Xtampza ER. Med Lett Drugs Ther. 2016;58(1497):77?78.

Post navigation

Effectiveness and tolerability of tapentadol sustained release in the Australian setting
Evaluation of the durability of pain relief throughout a 12?hour dosing interval of a novel, extended-release, abuse-deterrent formulation of oxycodone

Leave a Reply Cancel reply

You must be logged in to post a comment.

Collegium Pharmaceutical
  • info@collegiumpharma.com
  • (781) 713-3699
  • Privacy Policy
  • Terms of Use
  • Site Credits

© 2023